原发性中枢神经系统淋巴瘤的治疗新进展  

New Advances in the Treatment of Primary Central Nervous System Lymphoma——Review

作　　者：胡贝妮 杨翔 袁永平 陈懿建[2] HU Bei-Ni;YANG Xiang;YUAN Yong-Ping;CHEN Yi-Jian(Gannan Medical College,Ganzhou 341000,Jiangxi Province,China;Department of Hematology,The First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi Province,China)

机构地区：[1]赣南医学院,江西赣州341000 [2]赣南医学院第一附属医院血液科,江西赣州341000

出　　处：《中国实验血液学杂志》2021年第2期633-637,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金(81060047,81160073);江西省自然科学基金(20132BAB205053);江西省卫生厅重大项目基金(20114011);江西省教育厅科技落地计划(KJLD14085)。

摘　　要：原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的侵袭性淋巴结外非霍奇金淋巴瘤,目前基于甲氨蝶呤的大剂量化疗是新诊断的PCNSL的标准诱导治疗方案,但复发/难治性和老年PCNSL的有效治疗仍不明确,随着临床试验的进行,不断出现新的药物和联合治疗方法,如利妥昔单抗和依鲁替尼的加入增加了难治复发患者的缓解率,而来那度胺对老年患者的维持治疗显示出良好的活性,本文将对免疫检查点抑制剂、免疫调节药物、布鲁顿酪氨酸激酶和PI3K/AKT/mTOR通路抑制剂等最新研究进展作一综述。Primary central nervous system lymphoma(PCNSL)is a rare aggressive non-Hodgkin’s lymphoma outside the lymph nodes.At present,high-dose chemotherapy based on methotrexate is the standard induction therapy for newly diagnosed PCNSL,but the effective therapy of relapse/refractory and elderly PCNSL is still unclear.With the progress of clinical trials,new drugs and combined treatment method appear constantly,such as rituximab and ibrutinib,the remission rate of refractory and relapsed patients increased,while lenalidomide showed a good activity in the maintenance treatment of elderly patients.This review summarized briefly the recent advances of research on immunocheckpoint inhibitors,immunoregulatory agents,bruton tyrosine kinase(BTK)and PI3 K/AKT/mTOR pathway inhibitors.

关 键 词：原发性中枢神经系统淋巴瘤 化疗 免疫治疗 靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]